

No. 137

**WEST VIRGINIA LEGISLATURE**

**REGULAR SESSION, 1989**




**ENROLLED**

**SENATE BILL NO.** 137

(By Senator s J. Manchin, et al)



**PASSED** February 27, 1989

In Effect July 1, 1989 

**ENROLLED**

**Senate Bill No. 137**

(BY SENATORS J. MANCHIN, TUCKER, MR. PRESIDENT,  
BLATNIK, HOLLIDAY, FELTON, HARMAN, PRITT AND WARNER)

---

[Passed February 27, 1989; to take effect July 1, 1989.]

---

AN ACT to amend and reenact section twelve-b, article five, chapter thirty of the code of West Virginia, one thousand nine hundred thirty-one, as amended, relating to requirement that prescribing practitioner specify in his or her own handwriting "Brand Necessary" or "Brand Medically Necessary" or other designated language if generic drugs are not to be used to fill a prescription.

*Be it enacted by the Legislature of West Virginia:*

That section twelve-b, article five, chapter thirty of the code of West Virginia, one thousand nine hundred thirty-one, as amended, be amended and reenacted to read as follows:

**ARTICLE 5. PHARMACISTS, ASSISTANT PHARMACISTS AND  
DRUGSTORES.**

**§30-5-12b. Definitions; selection of generic drug products.**

- 1 (a) As used in this section:
- 2 (1) "Brand name" means the proprietary or trade
- 3 name selected by the manufacturer and placed upon a
- 4 drug or drug product, its container, label or wrapping
- 5 at the time of packaging.

6 (2) "Generic name" means the official title of a drug  
7 or drug combination for which a new drug application,  
8 or an abbreviated new drug application, has been  
9 approved by the United States food and drug admin-  
10 istration and is in effect.

11 (3) "Substitute" means to dispense without the  
12 prescriber's express authorization a therapeutically  
13 equivalent generic drug product in the place of the  
14 drug ordered or prescribed.

15 (4) "Equivalent" means drugs or drug products  
16 which are the same amounts of identical active  
17 ingredients and same dosage form, and which will  
18 provide essentially the same therapeutic efficacy and  
19 toxicity when administered to an individual.

20 (5) "Practitioner" means a physician, an authorized  
21 Type A physician assistant at the direction of his or  
22 her supervising physician in accordance with the  
23 provisions of section sixteen, article three of this  
24 chapter, osteopath, dentist, veterinarian, podiatrist,  
25 optometrist or any other person duly licensed to  
26 practice and to prescribe drugs under the laws of this  
27 state.

28 (b) A pharmacist who receives a prescription for a  
29 brand name drug or drug product shall substitute a  
30 less expensive equivalent generic name drug or drug  
31 product unless in the exercise of his or her profes-  
32 sional judgment the pharmacist believes that the less  
33 expensive drug is not suitable for the particular  
34 patient: *Provided*, That no substitution may be made  
35 by the pharmacist where the prescribing practitioner  
36 indicates that, in his or her professional judgment, a  
37 specific brand name drug is medically necessary for a  
38 particular patient. Every drug prescription order shall  
39 contain an instruction on whether or not an equiva-  
40 lent generic name drug or drug product may be  
41 substituted.

42 A written prescription order shall permit the phar-  
43 macist to substitute an equivalent generic name drug  
44 or drug product except where the prescribing practi-  
45 tioner has indicated in his or her own handwriting the

46 words "Brand Necessary" or "Brand Medically Neces-  
47 sary." The following sentence shall be printed on the  
48 prescription form: "This prescription may be filled  
49 with a generically equivalent drug product unless the  
50 words 'Brand Necessary' or the words 'Brand  
51 Medically Necessary' are written, in the practitioner's  
52 own handwriting, on this prescription form."

53 A verbal prescription order shall permit the phar-  
54 macist to substitute an equivalent generic name drug  
55 or drug product except where the prescribing practi-  
56 tioner or his or her agent shall indicate to the pharma-  
57 cist that the prescription is "Brand Necessary" or  
58 "Brand Medically Necessary." The pharmacist shall  
59 note the instructions on the file copy of the prescrip-  
60 tion or chart order form.

61 (c) No person may by trade rule, work rule, contract,  
62 or in any other way prohibit, restrict, limit or attempt  
63 to prohibit, restrict or limit the making of a generic  
64 name substitution under subsection (b) of this section.  
65 No employer or his or her agent may use coercion or  
66 other means to interfere with the professional judg-  
67 ment of the pharmacist in deciding which generic  
68 name drugs or drug products shall be stocked or  
69 substituted: *Provided*, That this section shall not be  
70 construed to permit the pharmacist to generally refuse  
71 to substitute less expensive therapeutically equivalent  
72 generic drugs for brand name drugs, and that any  
73 pharmacist so refusing shall be subject to the penalties  
74 prescribed in section twenty-two, article five, chapter  
75 thirty of this code.

76 (d) A pharmacist may substitute a drug under  
77 subsection (b) of this section only where there will be  
78 a savings to the buyer. Where substitution is proper  
79 under subsection (b), or where the practitioner  
80 prescribes the drug by generic name, the pharmacist  
81 shall, consistent with his or her professional judgment,  
82 dispense the lowest retail cost, effective brand which  
83 is in stock.

84 (e) All savings in the retail price of the prescription  
85 shall be passed on to the purchaser; these savings shall

86 be equal to the difference between the retail price of  
87 the brand name product and the customary and usual  
88 price of the generic product substituted therefor:  
89 *Provided*, That in no event shall such savings be less  
90 than the difference in acquisition cost of the brand  
91 name product prescribed and the acquisition cost of  
92 the substituted product.

93 (f) Each pharmacy shall maintain a record of any  
94 substitution of an equivalent generic name drug  
95 product for a prescribed brand name drug product on  
96 the file copy of a written or verbal prescription or  
97 chart order. Such record shall include the manufac-  
98 turer and generic name of the drug product selected.

99 All drugs shall be labeled in accordance with the  
100 instructions of the practitioner.

101 Unless the practitioner directs otherwise, the pre-  
102 scription label on all drugs dispensed by the pharma-  
103 cist shall indicate the generic name using  
104 abbreviations if necessary and the name of the man-  
105 ufacturer. The same notation will be made on the  
106 original prescription retained by the pharmacist.

107 (g) A pharmacist may not dispense a product under  
108 the provisions of this section unless the manufacturer  
109 has shown that the drug has been manufactured with  
110 the following minimum good manufacturing standards  
111 and practices by:

112 (1) Labeling products with the name of the original  
113 manufacturer and control number;

114 (2) Maintaining quality control standards equal to or  
115 greater than those of the United States food and drug  
116 administration;

117 (3) Marking products with identification code or  
118 monogram; and

119 (4) Labeling products with an expiration date.

120 (h) The West Virginia board of pharmacy shall  
121 establish by rule a formulary of generic type and  
122 brand name drug products which are determined by  
123 the board to demonstrate significant biological or

124 therapeutic inequivalence and which, if substituted,  
125 would pose a threat to the health and safety of patients  
126 receiving prescription medication. The formulary shall  
127 be promulgated by the board within ninety days of the  
128 date of passage of this section, and may be amended in  
129 accordance with the provisions of chapter twenty-  
130 nine-a of this code.

131 (i) No pharmacist shall substitute a generic named  
132 therapeutically equivalent drug product for a  
133 prescribed brand name drug product if the brand  
134 name drug product or the generic drug type is listed  
135 on the formulary established by the West Virginia  
136 board of pharmacy pursuant to this article, or is found  
137 to be in violation of the requirements of the United  
138 States food and drug administration.

139 (j) Any pharmacist who substitutes any drug shall,  
140 either personally or through his or her agent, assistant  
141 or employee, notify the person presenting the pre-  
142 scription of such substitution. The person presenting  
143 the prescription shall have the right to refuse the  
144 substitution. Upon request the pharmacist shall relate  
145 the retail price difference between the brand name  
146 and the drug substituted for it.

147 (k) Every pharmacy shall post in a prominent place  
148 that is in clear and unobstructed public view, at or  
149 near the place where prescriptions are dispensed, a  
150 sign which shall read: "West Virginia law requires  
151 pharmacists to substitute a less expensive generic  
152 named therapeutically equivalent drug for a brand  
153 name drug, if available, unless you or your physician  
154 direct otherwise." The sign shall be printed with  
155 lettering of at least one and one-half inches in height  
156 with appropriate margins and spacing as prescribed by  
157 the West Virginia board of pharmacy.

158 (l) The West Virginia board of pharmacy shall  
159 promulgate rules and regulations setting standards for  
160 substituted drug products, obtaining compliance with  
161 the provisions of this section and enforcing the  
162 provisions of this section. Any person shall have the  
163 right to file a complaint with the West Virginia board

164 of pharmacy regarding any violation of the provisions  
165 of this article. Such complaints shall be investigated by  
166 the board of pharmacy.

167 Fifteen days after the board has notified, by regis-  
168 tered mail, a person, firm, corporation or  
169 copartnership that such person, firm, corporation or  
170 copartnership is suspected of being in violation of a  
171 provision of this section, the board shall hold a hearing  
172 on the matter. If, as a result of the hearing, the board  
173 determines that a person, firm, corporation or  
174 copartnership is violating any of the provisions of this  
175 section, it may, in addition to any penalties prescribed  
176 by section twenty-two of this article, suspend or  
177 revoke the permit of any person, firm, corporation or  
178 copartnership to operate a pharmacy or drugstore.

179 (m) No pharmacist complying with the provisions of  
180 this section shall be liable in any way for the  
181 dispensing of a generic named therapeutically equiva-  
182 lent drug, substituted under the provisions of this  
183 section, unless the generic named therapeutically  
184 equivalent drug was incorrectly substituted.

185 In no event where the pharmacist substitutes a drug  
186 under the provisions of this section shall the  
187 prescribing physician be liable in any action for loss,  
188 damage, injury or death of any person occasioned by  
189 or arising from the use of the substitute drug unless  
190 the original drug was incorrectly prescribed.

191 Failure of a practitioner to specify that a specific  
192 brand name is necessary for a particular patient shall  
193 not constitute evidence of negligence unless the  
194 practitioner had reasonable cause to believe that the  
195 health of the patient required the use of a certain  
196 product and no other.

The Joint Committee on Enrolled Bills hereby certifies that the foregoing bill is correctly enrolled.

*Frederick L. Parker*  
.....  
Chairman Senate Committee

*J. L. Letts*  
.....  
Member  
Chairman House Committee

Originated in the Senate.

To take effect July 1, 1989.

*Joseph C. Mueller*  
.....  
Clerk of the Senate

*Donald J. Hoop*  
.....  
Clerk of the House of Delegates

*Sam D. Tucker*  
.....  
President of the Senate

*W. C. [unclear]*  
.....  
Speaker House of Delegates

The within is approved this the *8th* day of *March*, 1989.

*Gaston Caperton*  
.....  
Governor



PRESENTED TO THE

GOVERNOR

Date 3/02

Time 11:00